Background: Since bromodomain-containing protein 4 (BRD4) facilitates the transcription of
genes important for neoplastic cells in a cancer-type specific manner, BRD4-regulated …

Mantle cell lymphoma (MCL) is a subtype of non-Hodgkin's lymphoma characterized by poor
prognosis. The complexity of MCL pathogenesis arises from aberrant activities of diverse …

Signal transduction through the constitutively activated B cell receptor (BCR) plays a key
role in the pathogenesis of B-cell tumors by promoting survival and proliferation of malignant …

Mantle cell lymphoma (MCL), a B-cell non-Hodgkin lymphoma, remains incurable with
current treatment modalities. Bruton tyrosine kinase (BTK), a key component of the early …

Mantle cell lymphoma (MCL) is a rare and aggressive form of non-Hodgkin's B-cell
lymphoma and represents 4% to 8% of NHL. New therapeutic strategies are under …

Mantle cell lymphoma (MCL) is an aggressive B cell lymphoma that is largely
chemoresistant. Ibrutinib, a drug that inhibits Bruton's tyrosine kinase (BTK), has improved …

Mantle Cell Lymphoma (MCL) is still an incurable B-cell malignancy characterized by poor
prognosis and frequent relapses. B Cell Receptor (BCR) signaling inhibitors, in particular of …

Background: Aberrant B-cell receptor signaling is an important contributor to
lymphomagenesis in mantle cell lymphoma (MCL). Bruton's Tyrosine Kinase (BTK), a …

Background Mantle cell lymphoma (MCL) is an aggressive and incurable form of non-
Hodgkin's lymphoma. Despite initial intense chemotherapy, up to 50% of cases of MCL …

Targeting Bruton tyrosine kinase (BTK) by ibrutinib is an effective treatment for patients with
relapsed/refractory mantle cell lymphoma (MCL). However, both primary and acquired …